Leuprolide Acetate Market Report 2026

Leuprolide Acetate Market Overview

• Leuprolide Acetate market size has reached to $2.71 billion in 2025 • Expected to grow to $3.71 billion in 2030 at a compound annual growth rate (CAGR) of 6.4% • Growth Driver: Rising Prostate Cancer Incidence Driving The Growth Of The Market Due To Aging Population And Hormone Therapy Demand • Market Trend: Advancements In Patient-Administered Leuprolide Acetate Improve Therapy Adherence And Accessibility • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Leuprolide Acetate Market?

Leuprolide acetate is a synthetic gonadotropin-releasing hormone (GnRH) agonist used primarily to suppress hormone production. It reduces levels of estrogen and testosterone by initially stimulating and subsequently suppressing the pituitary gland. Its primary purpose is to treat hormone-sensitive conditions such as prostate cancer, endometriosis, uterine fibroids, and precocious puberty. The main types of products in leuprolide acetate are vials, prefilled syringes, and lyophilized powder. Vials are small glass or plastic containers used to store leuprolide acetate in liquid form for injection. It is administered through intramuscular, subcutaneous, intranasal, and implantation methods and distributed through hospital pharmacies, retail pharmacies, and online pharmacies. It finds applications in prostate cancer, endometriosis, uterine fibroids, central precocious puberty, infertility, hormone therapy, and others, catering to various end users including hospitals, clinics, home care settings, and research laboratories.

What Is The Leuprolide Acetate Market Growth Forecast?

The leuprolide acetate market size is expected to see strong growth in the next few years. It will grow to $3.71 billion in 2030 at a compound annual growth rate (CAGR) of 6.4%. The growth in the forecast period can be attributed to aging male population, increasing uterine fibroid diagnosis, long-acting formulation demand, outpatient hormone therapy growth, fertility treatment expansion. Major trends in the forecast period include rising use in hormone-dependent disorders, expansion of long-acting depot formulations, growth of oncology and gynecology applications, increased preference for injectable hormonal therapies, product innovation in controlled release systems.

Global Leuprolide Acetate Market Segmentation

1) By Product: Vials, Prefilled Syringes, Lyophilized Powder 2) By Route Of Administration: Intramuscular, Subcutaneous 3) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy 4) By Application: Prostate Cancer, Endometriosis, Uterine Fibroids, Central Precocious Puberty, Other Applications 5) By End-User: Hospitals, Clinics, Homecare Settings, Research Laboratories Subsegments: 1) By Vials: Single-Dose Vials, Multi-Dose Vials 2) By Prefilled Syringes: Disposable Prefilled Syringes, Reusable Prefilled Syringes 3) By Lyophilized Powder: Powder For Reconstitution, Ready-To-Mix Formulations

What Is The Driver Of The Leuprolide Acetate Market?

The increasing prevalence of prostate cancer is expected to propel the growth of the leuprolide acetate market going forward. Prostate cancer is a type of cancer that develops in the glandular cells of the prostate, a male-specific organ located below the bladder, and is one of the most common cancers among men worldwide. The increasing incidence of prostate cancer is primarily due to the aging population, as the risk of developing the disease rises significantly with age. Leuprolide acetate supports prostate cancer treatment by lowering testosterone levels, which helps slow tumor growth and manage advanced disease, improving patient outcomes. For instance, in January 2025, according to the Centers for Disease Control and Prevention, a US-based government administration, in the United States, 255,395 new cases of prostate cancer were reported in 2022, and 33,881 men died from the disease in 2023. Therefore, the increasing prevalence of prostate cancer is driving the growth of the leuprolide acetate industry.

Key Players In The Global Leuprolide Acetate Market

Major companies operating in the leuprolide acetate market are Abbott Laboratories, Teva Pharmaceutical Industries Ltd., Viatris Inc., Sandoz International GmbH, Apotex Inc., Aurobindo Pharma Limited, Lupin Limited, Baxter International Inc., Accord Healthcare Ltd., Glenmark Pharmaceuticals Limited, Strides Pharma Science Limited, Amring Pharmaceuticals Inc., MSN Laboratories Pvt Ltd., Wockhardt Limited, Bharat Parenterals Limited, Reliance Life Sciences Pvt Ltd., Nanjing Chia Tai Tianqing Pharmaceutical Co. Ltd., Zhejiang Hisun Pharmaceutical Co. Ltd., Livzon Pharmaceutical Group Inc., Harbin Pharmaceutical Group Co. Ltd., Hengrui Medicine Co. Ltd., CSPC Pharmaceutical Group Limited, Qilu Pharmaceutical Co. Ltd., Kelun Pharmaceutical Co. Ltd., Chengdu Tiantaishan Pharmaceutical Co. Ltd., Beijing SL Pharmaceutical Co. Ltd.

Global Leuprolide Acetate Market Trends and Insights

Major companies operating in the leuprolide acetate market are focusing on developing innovative solutions, such as generic injectable formulations to increase accessibility and reduce treatment costs. Generic injectable formulations are non-branded versions of injectable drugs with the same active ingredients and dosage as the original, helping make treatments more affordable and widely accessible. For instance, in June 2025, Avenacy, a US-based specialty pharmaceutical company, launched Leuprolide Acetate Injection, a generic equivalent in a 14-day patient-administration kit. The kit comprises a 14 mg / 2.8 mL multi-dose vial (1 mg per 0.2 mL), 14 disposable syringes, and 28 alcohol wipes, allowing patients to safely self-administer doses over a two-week period. Designed to reduce the need for clinic-based dosing, the kit also offers cost savings, convenience, and optimized packaging for accurate medication selection, making it particularly suitable for retail and mail-order pharmacy distribution.

What Are Latest Mergers And Acquisitions In The Leuprolide Acetate Market?

In December 2023, Zydus Lifesciences Ltd., an India-based pharmaceutical company, entered into an exclusive licensing agreement with Daewoong Pharmaceutical Co. Ltd. to co-develop and commercialize leuprolide acetate for depot suspension. This collaboration aims to leverage Daewoong’s proprietary technology and formulation expertise alongside Zydus’s strong market presence to bring an advanced, long-acting hormonal therapy to global markets. Daewoong Pharmaceutical Co. Ltd. is a South Korea-based pharmaceutical company that focuses on innovative drug delivery and offers leuprolide acetate for hormone-related treatments.

Regional Insights

North America was the largest region in the leuprolide acetate market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Leuprolide Acetate Market?

The leuprolide acetate market consists of sales of long-acting depot injections and custom compounded forms. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Leuprolide Acetate Market Report 2026?

The leuprolide acetate market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the leuprolide acetate industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.